



Estrogen receptor α : a critical role in successful female cognitive aging

N. E. Baumgartner & J. M. Daniel

To cite this article: N. E. Baumgartner & J. M. Daniel (2021) Estrogen receptor α : a critical role in successful female cognitive aging, *Climacteric*, 24:4, 333-339, DOI: [10.1080/13697137.2021.1875426](https://doi.org/10.1080/13697137.2021.1875426)

To link to this article: <https://doi.org/10.1080/13697137.2021.1875426>



Published online: 01 Feb 2021.



Submit your article to this journal [↗](#)



Article views: 297



View related articles [↗](#)



View Crossmark data [↗](#)



Citing articles: 1 View citing articles [↗](#)

REVIEW



Estrogen receptor α : a critical role in successful female cognitive aging

N. E. Baumgartner^{a,b} and J. M. Daniel^{a,b,c}

^aNeuroscience Program, Tulane University, New Orleans, LA, USA; ^bBrain Institute, Tulane University, New Orleans, LA, USA; ^cDepartment of Psychology, Tulane University, New Orleans, LA, USA

ABSTRACT

Due to potential health risks, current recommendations are that individuals who wish to use hormone therapy to treat menopausal symptoms do so for the shortest period of time possible. In our investigation into how short-term use of estrogens in midlife following loss of ovarian function exerts long-term effects on female cognitive aging in rodents, we discovered a link between the ability of previous exposure to estradiol to enhance memory in the long term and its ability to increase estrogen receptor α (ER α) levels in the hippocampus, a brain area important for memory. Follow-up studies in model systems implicate a role for ER α in enhanced cognitive function independent of ovarian or exogenously administered estrogens. Results are consistent with clinical studies in which brain ER α levels in older women and men are related to cognitive functioning and risk of cognitive decline is associated with polymorphisms in the gene that transcribes ER α . Research in preclinical models reveals mechanisms through which ER α can be activated and affect cognition in the absence of ovarian estrogens, including ligand-independent activation via insulin-like growth factor-1 signaling and activation by brain-derived neuroestrogens. This report reviews preclinical and clinical data that collectively point to the importance of ER α in cognition and highlights the need to differentiate the role of estrogen receptors from their classical ligands as we seek approaches to facilitate successful cognitive aging.

ARTICLE HISTORY

Received 4 August 2020
Revised 30 November 2020
Accepted 28 December 2020
Published online 1 February 2021

KEYWORDS

Estrogen receptor α ;
estrogens; hippocampus;
brain; cognition; aging;
insulin-like growth factor-1;
neuroestrogens; meno-
pause; Alzheimer's disease

Introduction

The loss of ovarian hormones during menopause coincides with cognitive decline and increased risk of age-related dementia including Alzheimer's disease (AD)^{1,2}. Several decades of research provide convincing evidence that estrogens play a neuroprotective role in the brain^{3,4}. Thus, expectations were that menopausal hormone therapy would provide benefits to the brain and cognition. In fact, early reports indicated that estrogens used during or near menopause reduced the risk and severity of AD^{5,6}. However, results from the large Women's Health Initiative Memory Study (WHIMS) conducted by the National Institutes of Health indicated that conjugated equine estrogen therapy resulted in small long-term deficits in cognitive function, smaller brain volumes, and increased risk of dementia^{7–9}. Following these unexpected results, attention was focused on various factors related to the experimental design including type of estrogen administered and tests used to assess cognition. Attention also focused on the importance of the timing of initiation of hormone therapy. In the WHIMS, hormone therapy was administered to women aged 65 years and older (mean age of 73 years) and well after ovarian hormone levels have declined at menopause. The critical period hypothesis, which proposes that cognitive benefits of estrogens may only be apparent if administered near the time of menopause, is viewed as a possible explanation for discrepant results across studies¹⁰. Although existing clinical data

provide some support for the critical period hypothesis of estrogen effects in women¹¹, recent results from the Kronos Early Estrogen Prevention Study (KEEPS) indicate no harm, but also no benefit, of either oral conjugated equine estrogens or transdermal 17 β -estradiol (estradiol) in healthy recently postmenopausal women¹². Ongoing clinical trials such as the KEEPS should provide more insight as women enrolled in the study reach ages at which cognitive decline is more prevalent.

Following publication of the Women's Health Initiative study results, long-term use of menopausal hormone therapy dropped significantly¹³. Furthermore, because of concerns regarding putative health risks¹⁴ (but see¹⁵), the US Food and Drug Administration (FDA) now recommends that women who wish to use hormone therapy to treat menopausal symptoms should limit its use for the shortest time period possible¹⁶. Because hormone therapy is now recommended to be used for only a few years near menopause, understanding if and how short-term exposure to estrogens exert long-term effects on the brain and cognitive aging trajectory has become critical.

In our own work investigating the long-term impacts of short-term use of estrogens on the brain and memory in a preclinical rodent model, we have identified an intriguing role for brain estrogen receptors, in the absence of ovarian or exogenous estrogens, in successful cognitive and brain aging. Consistent with experimental evidence are clinical studies that point to a potential relationship between brain

estrogen receptor and cognitive aging. The current report provides an overview of the research from across the translational science spectrum that points to estrogen receptor α (ER α) as a vital mediator of cognitive function during aging and highlights the importance of the translational link between preclinical and clinical research, in which results from each can inform questions asked by the other.

Lasting impact for cognition of short-term estrogen use in midlife: a role for ER α

Based on current recommendations that women use hormone therapy, if needed, for a short time, we employed a rodent model to empirically test whether short-term previous exposure to estrogens in middle age had lasting impact on cognition. We found that, in rodents, short-term treatment with estrogens in midlife produce similar benefits for memory to that of continuous estradiol treatment without the prolonged exposure to hormones (see Figure 1(A)). Rats that received 40 days of estradiol treatment (roughly comparable to 3.5 years in women) immediately following ovariectomy in midlife displayed enhanced performance on a hippocampal-dependent radial-maze memory task up to 7 months after hormone treatment had been terminated¹⁷. These rats previously treated with estradiol showed comparable performance on the radial-arm maze to animals continuously receiving estradiol treatment throughout the experiment, demonstrating that short-term exposure to estradiol near the start of loss of ovarian function can have similar cognitive benefits to ongoing estrogen use. More recently, similar results have been found in non-human primates. Ovariectomized rhesus monkeys that received 11 months of cyclic estradiol injections displayed enhanced memory when tested 1 year after hormone treatments had ended¹⁸. These results provide evidence across species that midlife estradiol use can impact the brain and cognition via mechanisms that persist long after hormone exposure is terminated. Identifying the long-term changes in the brain resulting from midlife estradiol use can therefore provide new avenues for combating age-related cognitive decline that avoid traditional long-term hormone treatment.

In our exploration into how short-term exposure to estrogens can exert long-term impacts on the brain, we found that, in parallel to effects on memory, previous exposure to estradiol in midlife results in increased levels of ER α , but not ER β , in the hippocampus up to 8 months after hormone treatment had ended¹⁷. Importantly, the effects of previous exposure to estradiol on ER α were identical to those of animals that received ongoing estradiol treatment. This lasting increase in ER α resulting from previous treatment with estradiol following loss of ovarian function has been replicated in several studies^{19,20}. In addition to the impact on hippocampal levels of ER α , previous estradiol treatment results in lasting increases in choline acetyltransferase (ChAT) expression^{17,19}, phosphorylation of p42 mitogen-activated protein kinase (MAPK)¹⁹, and estrogen receptor-mediated transcriptional activity²¹ in the hippocampus. The long-lasting elevation of ER α protein levels and downstream

mediators of cognitive function in the hippocampus following previous exposure to estradiol in midlife provide mechanistic evidence for a role for ER α in enhancing cognition in the absence of ovarian hormones.

Impacts of ER α on cognitive and brain aging in the absence of ovarian or exogenously administered estrogens

Our findings in a preclinical rodent model of female cognitive aging of elevated brain ER α levels and lasting memory enhancements that persist long after termination of midlife estradiol treatment led us to examine the clinical literature for evidence of a role of ER α in cognitive aging in humans. An overview of that literature is presented in Table 1.

In brief summary, similar to what we found in our preclinical model, levels of ER α in brain areas important for cognition are associated with cognitive and/or brain function in humans. For example, in both men and women with AD, increased levels of the full-length 66-kDa isoform of ER α in the frontal cortex are associated with better performance on cognitive tests²², suggesting that levels of ER α in the brain may modulate cognition in AD patients. Additionally, nuclear expression of ER α protein levels in the CA1 and CA2 regions of the hippocampus is decreased in brains of women with AD as compared to those of age-matched controls²³. Similarly, mRNA expression of *Esr1*, the gene that encodes ER α , is decreased in the brains of women with AD as compared to those of age-matched controls²⁴.

Further supporting a role for ER α in cognitive aging are results that implicate polymorphisms in *Esr1* in both pathological and non-pathological cognitive decline. For example, there are several reports of an increased risk of AD in men and women with certain *Esr1* polymorphisms^{25–27}, although not all studies agree on which specific *Esr1* polymorphisms are relevant. Additionally, *Esr1* polymorphisms may act as effect modifiers for risk of AD in carriers of the *APOE* $\epsilon 4$ allele²⁸ and interact with *APOE* polymorphisms to impact cognition²⁹. However, in contrast to these results are data that show no association between estrogen receptor genotype and susceptibility to late-onset AD³⁰. In addition to potential effects on the risk of AD, *Esr1* polymorphisms have been implicated in non-pathological cognitive decline^{31,32}. Interestingly, the increased risk of cognitive decline associated with *Esr1* polymorphisms in women was found to be independent of menopausal estrogen use³³. However, certain polymorphisms can modulate the effect of estrogens on cognitive function³⁴, suggesting that variations in ER α expression might affect the efficacy of menopausal hormone treatments. Not all reports support the association between *Esr1* polymorphisms and cognitive decline. For example, in elderly women without dementia, associations were found between cognition and polymorphisms in *Esr2*, the gene that encodes ER β , but not for *Esr1* polymorphisms^{35,36}.

Although a more thorough and critical review of the clinical data related to the association of estrogen receptor and cognitive aging is warranted, collectively current data suggest a potential role for brain ER α in successful brain and




Figure 1. Evidence that estrogen receptor α (ER α) acts in the brain to enhance female cognitive aging in the absence of ovarian or exogenously administered estrogens. (A) Increased levels of brain ER α are associated with improved memory in the absence of ovarian or exogenous estrogens. Previous midlife estradiol treatment (Pre E) as compared to vehicle treatment (Pre Veh) in aging ovariectomized (OVX) rats enhances memory (decreased errors) on a radial-arm maze task (left) and increases protein levels of ER α in the hippocampus as measured by western blotting (right) 7 months after termination of estradiol treatment. (B) A causal relationship exists between increased levels or availability of brain ER α and enhanced memory in the absence of ovarian or exogenous estrogens. Overexpressing ER α in the hippocampus of aging OVX rats via lentiviral delivery (lenti-ER α ; left) enhances memory (decreased errors) on a radial-maze task as compared to a control virus (lenti-Cherry). Antagonizing brain ER via intraventricular infusion of the ER antagonist ICI 182,780 (ICI; right) in aging OVX rats impairs memory (increased errors) on the radial maze task as compared to infusion of artificial cerebrospinal fluid (aCSF) vehicle. (C) In the absence of ovarian or exogenous estrogens, ER α can be activated by at least two mechanisms. Ligand-independent activation occurs by growth factor signaling (left) in which an intraventricular infusion of insulin-like growth factor-1 (IGF-1) increases levels of phosphorylated ER α at S118 in the hippocampus of OVX rats as compared to infusion of aCSF vehicle. Brain-derived neuroestrogens can activate the receptor (right) in which mice that were OVX 10 days prior had similar levels of hippocampal ER-dependent transcription (i.e. Luciferase activity indicated by RLU/ μ g) to gonadally intact females. Chronic intraventricular infusion of the aromatase inhibitor letrozole, which blocks brain estradiol synthesis, blocks estrogen receptor-dependent transcription in the hippocampus. * $p < 0.05$. Adapted from ^{17,20,37,45,58}.

cognitive aging in humans. To test for a causal relationship of this association, we turned to our preclinical model.

Experimental evidence implicating brain ER α as a mediator of cognitive function in the absence of ovarian estrogens

To determine whether ER α can directly impact cognitive function in aged females following the loss of ovarian function, we used two approaches – increasing and decreasing availability of brain ER α in aging ovariectomized rats and assessing effects on memory (see Figure 1(B)). We first overexpressed ER α in the hippocampus of aged ovariectomized females using lentiviral delivery of the gene for the protein (lenti-ER α)³⁷. Aged females that received lenti-ER α outperformed rats that received a control virus on a hippocampus-dependent spatial memory task. In a second experiment, we blocked brain estrogen receptors in ovariectomized aging females that had previously undergone midlife estradiol treatment²⁰. Rats received chronic intracerebroventricular infusion via osmotic minipumps of the ER antagonist, ICI 162,780 (ICI), or artificial cerebrospinal fluid vehicle beginning after estradiol treatment was terminated. Rats treated with ICI had significantly worse memory on a radial-maze task than controls. Results reveal that increased levels or availability of ERs in the hippocampus lead to enhanced memory in the absence of ovarian or ongoing administration of estrogens. They provide support for the hypothesis that treatments that increase or maintain levels of ER α in aging females help to improve or maintain memory processes even in the absence of ovarian or exogenously administered estrogens.

In addition to its direct effects on memory, ER α plays a neuroprotective role in the brain. For instance, increased hippocampal ER α expression protects female neonatal mice following hypoxic ischemia³⁸, a time point before ovarian estrogen production begins but at which ER α can have a lasting impact on cognitive function through adulthood³⁹. This finding is particularly interesting considering the several studies that have shown the neuroprotective impacts of estrogens acting specifically through ER α following stroke in the aging brain^{40,41}. The protective functions of ER α have also been demonstrated in other brain regions and in males. In the nucleus accumbens, stress results in decreased levels of ER α and overexpression of ER α promotes resilience against chronic social defeat stress through transcriptional changes in both male and female mice⁴².

Together, data from preclinical models indicate an important role for estrogen receptors – independent of ovarian estrogens – in maintaining cognitive health across the lifespan.

Mechanisms by which brain ER α can be activated in the absence of circulating estrogens

In order for ER α to continue to impact cognition after loss of ovarian function, it must be activated by mechanisms independent of ovarian estrogens. Based on work from our

laboratory and others, we propose two mechanisms for sustained activation of ER α in the absence of ovarian estrogens: ligand-independent activation of ER α by growth factors including insulin-like growth factor-1 (IGF-1) and activation of the receptor by locally synthesized neuroestrogens (see Figure 1(C)).

Ligand-independent activation by IGF-1

Activation of estrogen receptor-dependent transcriptional activity in the absence of estrogens by growth factor was shown years ago *in vitro*⁴³. Specifically, IGF-1 is able to activate ER α through activation of the MAPK pathway resulting in phosphorylation of ER α at S118⁴⁴. More recently, work from our laboratory demonstrated a similar effect *in vivo*⁴⁵. Acute infusion of IGF-1 to the lateral ventricle of ovariectomized rats results in increased levels of pS118-ER α in the hippocampus 1 h after treatment, and increased levels of total ER α 24 h after treatment. Therefore, ligand-independent activation of ER α by IGF-1 provides a potential mechanism through which increased expression of ER α can enhance cognition in the absence of ovarian estrogens.

IGF-1 is a peptide hormone that acts as the major effector of the pituitary hormone growth hormone (GH). IGF-1 is structurally very similar to insulin and can bind to insulin receptors in addition to its own IGF-1 receptor (IGF-1R)⁴⁶. IGF-1 is necessary for neuronal development and regulates plasticity in the developing brain⁴⁷. Because of the critical role it plays in development, levels of IGF-1 change over the lifespan and ultimately decline in the brain with aging⁴⁸. Similar to the decline in estrogens following the loss of ovarian function, this decrease in IGF-1 coincides with increased risk of cognitive decline.

Studies in humans implicate IGF-1 signaling dysfunction in the pathology of age-related dementias including AD, although much debate remains about whether increased IGF-1 levels would be beneficial in combatting these disorders. For instance, IGF-1R expression levels were found to be decreased in the brains of patients with AD as compared to those of controls⁴⁹. On the other hand, work in animal models suggests that increased IGF-1R signaling contributes to the pathological formation of proteins associated with AD⁵⁰. Dysfunction in IGF-1 and insulin signaling likely plays a role in the pathology of AD, although the specific mechanisms remain unclear.

Studies in model systems have demonstrated that the effects of IGF-1 signaling in the brain overlap greatly with the impacts of estrogen receptor signaling and indicate that these two systems closely interact. Most neurons and some astrocytes in the rat brain that express IGF-1R also express either ER α or ER β , with particularly prevalent co-localization of IGF-1R and ER α in hippocampal neurons⁵¹. The interaction between these receptors goes beyond simply co-localization, however. ER α and IGF-1R have been shown to form estradiol-dependent protein complexes in the brains of ovariectomized rats⁵².

These interactions between ER α and IGF-1R are important for maintaining cognition in the aging brain. In

Table 1. Overview of results of clinical studies investigating the relationship between ER α and pathological and non-pathological age-related cognitive decline.

Authors	Reported population	Measures	Summary of findings	PMID/doi
<i>Studies supporting an association between ERα/Esr1 and cognitive outcomes</i>				
Bojar <i>et al.</i> ³⁴	Middle-aged women without dementia	Cognitive tests; E2 levels; <i>Esr1</i> polymorphisms	<i>Esr1</i> polymorphism modulated the effect of E2 on cognitive function	PMID: 27680398
Cheng <i>et al.</i> ²⁷	Meta-analysis of other studies	<i>Esr1</i> SNPs PvuII and XbaI; AD risk	<i>Esr1</i> PvuII SNP significantly increases risk of AD in Caucasian, but not Asian, women	PMID: 25061285
Corbo <i>et al.</i> ²⁶	AD patients and age-matched controls (men and women)	<i>Esr1</i> SNPs PvuII and XbaI; APOE plasma levels	<i>Esr1</i> SNPs PvuII and XbaI increased risk of AD in men only; in women, those SNPs increased the rate of cognitive decline	PMID: 16699281
Hu <i>et al.</i> ²³	AD patients and age-matched controls (women)	ER α localization in hippocampus	Decreased nuclear ER α staining in CA1 and CA2 of AD brains	PMID: 12819990
Ishunina <i>et al.</i> ²⁴	AD patients and age-matched controls (women)	<i>Esr1</i> mRNA and aromatase activity in hippocampus	Decreased <i>Esr1</i> mRNA (normal and splice variant) and decreased aromatase expression in AD hippocampi	PMID: 17010478
Kelly <i>et al.</i> ²²	AD patients (men and women)	Cognitive tests; ER α protein levels	Increased nuclear ER α in frontal cortex associated with better cognitive performance	PMID: 18288931
Ma <i>et al.</i> ²⁵	AD patients and age-matched controls (men and women)	<i>Esr1</i> SNPs; AD risk	Several <i>Esr1</i> SNPs associated with AD risk and age of onset	PMID: 19586561
Ma <i>et al.</i> ³²	Elderly men and women	<i>Esr1</i> SNPs; cognitive tests	Several <i>Esr1</i> polymorphisms associated with cognitive decline	PMID: 23567436
Pinkas <i>et al.</i> ²⁹	Postmenopausal women	<i>Esr1</i> and APOE polymorphisms; cognitive tests	Interactive effects with certain <i>Esr1</i> and APOE polymorphisms on memory	doi.org/10.5114/aoms.2018.72972
Ryan <i>et al.</i> ²⁸	Elderly men and women	<i>Esr1</i> polymorphisms; risk of AD and dementia	<i>Esr1</i> polymorphism slightly associated with increased AD risk in women, but <i>Esr1</i> polymorphism + APOE ϵ 4 allele increased the risk of AD	PMID: 23491264
Yaffe <i>et al.</i> ³³	Elderly women	Cognitive tests; <i>Esr1</i> SNPs	<i>Esr1</i> SNPs increase risk of cognitive impairment, independent of estrogen use	PMID: 11955468
Yaffe <i>et al.</i> ³¹	Elderly men and women without dementia	Cognitive tests; <i>Esr1</i> and <i>Esr2</i> SNPs	<i>Esr1</i> and <i>Esr2</i> SNPs increased the risk of cognitive impairment	PMID: 17889406
<i>Studies not supporting an association between ERα/Esr1 and cognitive outcomes</i>				
Fehsel <i>et al.</i> ³⁵	Elderly women without dementia	Cognitive tests; <i>Esr1</i> , <i>Esr2</i> , APOE SNPs	No association of <i>Esr1</i> SNPs with cognitive effects but did see effects for <i>Esr2</i> and some interaction of <i>Esr2</i> with APOE SNPs	PMID: 27629499
Goumidi <i>et al.</i> ³⁰	AD patients and age-matched controls (men and women)	<i>Esr1</i> and <i>Esr2</i> SNPs; late-onset AD risk	No association of <i>Esr1</i> or <i>Esr2</i> SNPs with late-onset AD risk	PMID: 21673408
Ryan <i>et al.</i> ³⁶	Elderly women without dementia	Cognitive tests; <i>Esr1</i> and <i>Esr2</i> polymorphisms	Five common <i>Esr1</i> polymorphisms not associated with cognitive impairment, but some effect of <i>Esr2</i> polymorphisms	PMID: 23932494

AD, Alzheimer's disease; APOE, apolipoprotein E; E2, estradiol; ER α , estrogen receptor α ; SNP, single-nucleotide polymorphism.

ovariectomized rats treated with continuous exposure to estradiol, antagonizing IGF-1R with JB1 directed to the lateral ventricle blocked the ability of estradiol to enhance performance on the radial-arm maze and increase hippocampal expression of synaptic proteins PSD-95 and spinophilin⁵³. Furthermore, JB1 blocks the memory enhancements and increased hippocampal expression of ER α , ChAT, and phosphorylated p42 MAPK in ovariectomized rats previously treated with estradiol during midlife¹⁹. These findings demonstrate that IGF-1R modulates the ability of ER α to impact

memory and hippocampal function in both the presence and the absence of circulating estrogens.

Neuroestrogen activation of ER α

In addition to ligand-independent activation, following loss of ovarian function, estrogen receptors may be activated by locally synthesized estradiol. These brain-derived neuroestrogens are capable of being synthesized throughout the human brain – including in the hippocampus, cerebral

cortex, hypothalamus, and amygdala, among others – as indicated by widespread expression of aromatase, the enzyme that synthesizes estradiol from testosterone⁵⁴. Because aromatase inhibitors are used in breast cancer treatments postmenopause, there are clinical insights into the role of neuroestrogens in cognition – presumably due to activation of estrogen receptors – in the absence of ovarian estrogens. Many, but not all, studies demonstrate that the use of aromatase inhibitors can negatively impact cognitive function in humans (for a meta-analysis, see⁵⁵). Interestingly, the use of aromatase inhibitors is associated with decreased hippocampal activity and impaired memory function in postmenopausal women⁵⁶. However, the lack of randomized clinical trials investigating the role of aromatase inhibitors in cognitive function limits the ability to draw conclusions as to the role of neuroestrogens in estrogen receptor function in the absence of ovarian estrogens.

Preclinical model systems have been used to empirically test the effects of aromatase inhibitors on hippocampal memory and estrogen receptor function. Chronic systemic administration of the aromatase inhibitor letrozole, which blocks estradiol synthesis including neuroestrogens, was recently shown to impair spatial memory performance in male and female gonadectomized marmosets⁵⁷. Additionally, we recently showed in a mouse model that neuroestrogens are able to impact estrogen receptor-dependent transcription in the brain for a short term, but not a long term, following ovariectomy⁵⁸. Further work is necessary to fully elucidate the long-term role of neuroestrogens in mediating estrogen receptor-dependent activity in the brain after loss of ovarian function. Interestingly, recent findings from our laboratory show a potential interaction between neuroestrogens and IGF-1 in sustaining ER α activity in the absence of ovarian estrogens⁵⁹.

Conclusion

Across multiple species and paradigms, an increasing body of literature suggests an important role for ER α in maintaining cognitive function in aging females in the absence of ovarian or exogenously administered estrogens. Clinical studies have revealed that variability in expression of ER α in older women (and men) is associated with variability in risk of cognitive impairment. Ongoing work in preclinical model systems is providing valuable insight into the mechanisms through which ER α enhances memory in aging females. Moving forward, identification of factors that contribute to variability in levels of brain ER α during aging, likely including previous use of menopausal estrogen therapy in midlife and perhaps environmental factors such as stress⁴², may lead to novel approaches to cognitive aging that capitalize on the potential of ER α to positively impact the aging brain.

Potential conflict of interest The authors report no conflict of interest. The authors alone are responsible for the content and writing of the article.

Source of funding Work described in this review that was conducted in our laboratory was supported by the National Institute on Aging [Grant RF1AG041374].

References

1. Pike CJ. Sex and the development of Alzheimer's disease. *J Neurosci Res* 2017;95:671–80
2. Scheyer O, Rahman A, Hristov H, et al. Female sex and Alzheimer's risk: the menopause connection. *J Prev Alzheimer's Dis* 2018;5: 225–30
3. Engler-Chiurazzi EB, Singh M, Simpkins JW. From the 90's to now: a brief historical perspective on more than two decades of estrogen neuroprotection. *Brain Res* 2016;1633:96–100
4. Luine V, Frankfurt M. Estrogenic regulation of memory: the first 50 years. *Horm Behav* 2020;121:104711
5. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore longitudinal study of aging. *Neurology* 1997;48:1517–21
6. Tang M, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. *Lancet* 1996;348:429–32
7. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: women's health initiative memory study. *JAMA* 2004;291: 2959–68
8. Shumaker SA, Legault C, Kuller L, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women's Health Initiative Memory Study. *JAMA* 2004;291:2947–58
9. Coker LH, Espeland MA, Hogan PE, et al. Change in brain and lesion volumes after CEE therapies: the WHIMS-MRI studies. *Neurology* 2014;82:427–34
10. Craig MC, Maki PM, Murphy DG. The women's health initiative memory study: findings and implications for treatment. *Lancet Neurol* 2005;4:190–4
11. Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. *Menopause* 2013; 20120:695–709
12. Miller VM, Naftolin F, Asthana S, et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? *Menopause* 2019;26:1071–84
13. Lobo RA. Where are we 10 years after the Women's Health Initiative? *J Clin Endocrinol Metab* 2013;98:1771–80
14. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive breast cancer. *Arch Intern Med* 2006;166:1027–32
15. Harman SM, Vittinghoff E, Brinton EA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. *Am J Med* 2011;124:199–205
16. National Institute on Aging. Hot flashes: what can I do? National Institute of Health; 2017. <https://www.nia.nih.gov/health/hot-flashes-what-can-i-do>
17. Rodgers SP, Bohacek J, Daniel JM. Transient estradiol exposure during middle age in ovariectomized rats exerts lasting effects on cognitive function and the hippocampus. *Endocrinology* 2010;151: 1194–203
18. Baxter M, Santistevan A, Bliss-Moreau E, et al. Timing of cyclic estradiol treatment differentially affects cognition in aged female rhesus monkeys. *Behav Neurosci* 2018;132:213–23
19. Witty CF, Gardella LP, Perez MC, et al. Short-term estradiol administration in aging ovariectomized rats provides lasting benefits for memory and the hippocampus: a role for insulin-like growth factor-I. *Endocrinology* 2013;154:842–52
20. Black KL, Witty CF, Daniel JM. Previous midlife oestradiol treatment results in long-term maintenance of hippocampal oestrogen receptor alpha levels in ovariectomised rats: mechanisms and implications for memory. *J Neuroendocrinol* 2016;28:1–10

21. Pollard KJ, Wartman HD, Daniel JM. Previous estradiol treatment in ovariectomized mice provides lasting enhancement of memory and brain estrogen receptor activity. *Horm Behav* 2018;102:76–84
22. Kelly JF, Bienias JL, Shah A, et al. Levels of estrogen receptors alpha and beta in frontal cortex of patients with Alzheimer's disease: relationship to mini-mental state examination scores. *Curr Alzheimer Res* 2008;5:45–51
23. Hu X, Qin S, Lu Y, et al. Decreased estrogen receptor-alpha expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. *Acta Neuropathol* 2003;106:213–20
24. Ishunina T, Fischer D, Swaab D. Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer's disease. *Neurobiol Aging* 2007;28:11
25. Ma S, Tang N, Tam C, et al. Polymorphisms of the estrogen receptor alpha (ESR1) gene and the risk of Alzheimer's disease in a southern Chinese community. *Int Psychogeriatr* 2009;21:977–86
26. Corbo RM, Gambina G, Ruggeri M, et al. Association of estrogen receptor alpha (ESR1) PvuII and XbaI polymorphisms with sporadic Alzheimer's disease and their effect on apolipoprotein E concentrations. *Dement Geriatr Cogn Disord* 2006;22:67–72
27. Cheng D, Liang B, Hao Y, et al. Estrogen receptor α gene polymorphisms and risk of Alzheimer's disease: evidence from a meta-analysis. *Clin Interv Aging* 2014;9:1031–8
28. Ryan J, Carriere I, Carcaillon L, et al. Estrogen receptor polymorphisms and incident dementia: the prospective 3C study. *Alzheimers Dement* 2014;10:27–35
29. Pinkas J, Bojar I, Gujski M, et al. Effect of interactions between APOE and ESR1 polymorphisms on cognitive functions in postmenopausal women. *Arch Med Sci* 2018;17:31–9
30. Goumidi L, Dahlman-Wright K, Tapia-Paez I, et al. Study of estrogen receptor- α and receptor- β gene polymorphisms on Alzheimer's disease. *JAD* 2011;26:431–9
31. Yaffe K, Lindquist K, Sen S, et al. Estrogen receptor genotype and risk of cognitive impairment in elders: findings from the Health ABC study. *Neurobiol Aging* 2009;30:607–14
32. Ma SL, Tang NL, Leung GT, et al. Estrogen receptor α polymorphisms and the risk of cognitive decline: a 2-year follow-up study. *Am J Geriatr Psychiatry* 2014;22:489–98
33. Yaffe K, Lui LY, Grady D, et al. Estrogen receptor 1 polymorphisms and risk of cognitive impairment in older women. *Biol Psychiatry* 2002;51:677–82
34. Bojar I, Pinkas J, Wierzbicka-Stępnik A, et al. Cognitive functions, concentration of endogenous estradiol, estrogen receptor α (ER α) polymorphism in postmenopausal women. *Med Sci Monit* 2016;22:3469–78
35. Fehsel K, Schikowski T, Jänner M, et al. Estrogen receptor beta polymorphisms and cognitive performance in women: associations and modifications by genetic and environmental influences. *J Neural Transm (Vienna)* 2016;123:1369–79
36. Ryan J, Carrière I, Amieva H, et al. Prospective analysis of the association between estrogen receptor gene variants and the risk of cognitive decline in elderly women. *Eur Neuropsychopharmacol* 2013;23:1763–8
37. Witty CF, Foster TC, Semple-Rowland SL, et al. Increasing hippocampal estrogen receptor alpha levels via viral vectors increases MAP kinase activation and enhances memory in aging rats in the absence of ovarian estrogens. *PLoS One* 2012;7:e51385
38. Cikla U, Chanana V, Kintner DB, et al. ER α signaling is required for TrkB-mediated hippocampal neuroprotection in female neonatal mice after hypoxic ischemic encephalopathy(1,2,3). *eNeuro* 2016;3:ENEURO.0025-15.2015.
39. Zafer D, Aycan N, Ozaydin B, et al. Sex differences in hippocampal memory and learning following neonatal brain injury: is there a role for estrogen receptor- α ? *Neuroendocrinology* 2019;109:249–56
40. Dubal DB, Rau SW, Shughrue PJ, et al. Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death. *Endocrinology* 2006;147:3076–84
41. Dubal DB, Zhu H, Yu J, et al. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. *Proc Natl Acad Sci USA* 2001;98:1952–7
42. Lorsch Z, Loh Y, Purushothaman I, et al. Estrogen receptor α drives pro-resilient transcription in mouse models of depression. *Nat Commun* 2018;9:1116
43. Ma Z, S Antagati S, Patrone C, et al. Insulin-like growth factors activate estrogen receptor to control the growth and differentiation of the human neuroblastoma cell line SK-ER3. *Mol Endocrinol (Baltimore)* 1994;8:910–18
44. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. *Science* 1995;270:1491–4
45. Grissom EM, Daniel JM. Evidence for ligand-independent activation of hippocampal estrogen receptor- α by IGF-1 in hippocampus of ovariectomized rats. *Endocrinology* 2016;157:3149–56
46. Russo VC, Gluckman PD, Feldman EL, et al. The insulin-like growth factor system and its pleiotropic functions in brain. *Endocr Rev* 2005;26:916–43
47. Arsenijevic Y, Weiss S, Schneider B, et al. Insulin-like growth factor-1 is necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth factor and fibroblast growth factor-2. *J Neurosci* 2001;21:7194–202
48. Sonntag W, Lynch C, Bennett S, et al. Alterations in insulin-like growth factor-1 gene and protein expression and type 1 insulin-like growth factor receptors in the brains of ageing rats. *Neuroscience* 1999;88:269–79
49. Moloney A, Griffin R, Timmons S, et al. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. *Neurobiol Aging* 2010;31:224–43
50. O'Neill C, Kiely AP, Coakley MF, et al. Insulin and IGF-1 signalling: longevity, protein homeostasis and Alzheimer's disease. *Biochem Soc Trans* 2012;40:721–7
51. Cardona-Gómez GP, DonCarlos L, Garcia-Segura LM. Insulin-like growth factor I receptors and estrogen receptors colocalize in female rat brain. *Neuroscience* 2000;99:751–60
52. Mendez P, Azcoitia I, Garcia-Segura L. Estrogen receptor alpha forms estrogen-dependent multimolecular complexes with insulin-like growth factor receptor and phosphatidylinositol 3-kinase in the adult rat brain. *Brain Res Mol Brain Res* 2003;112:170–6
53. Nelson BS, Springer RC, Daniel JM. Antagonism of brain insulin-like growth factor-1 receptors blocks estradiol effects on memory and levels of hippocampal synaptic proteins in ovariectomized rats. *Psychopharmacology (Berl)* 2014;231:899–907
54. Azcoitia I, Yague J, Garcia-Segura LM. Estradiol synthesis within the human brain. *Neuroscience* 2011;191:139–47
55. Lee PE, Tierney MC, Wu W, et al. Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. *Breast Cancer Res Treat* 2016;158:407–20
56. Bayer J, Rune G, Schultz H, et al. The effect of estrogen synthesis inhibition on hippocampal memory. *Psychoneuroendocrinology* 2015;56:213–25
57. Gervais N, Remage-Healey L, Starrett J, et al. Adverse effects of aromatase inhibition on the brain and behavior in a nonhuman primate. *J Neurosci* 2019;39:918–28
58. Baumgartner NE, Grissom EM, Pollard KJ, et al. Neuroestrogen-dependent transcriptional activity in the brains of ERE-luciferase reporter mice following short- and long-term ovariectomy. *eNeuro* 2019;6:ENEURO.0275-19.2019
59. Pollard KJ, Daniel JM. Nuclear estrogen receptor activation by insulin-like growth factor-1 in Neuro-2A neuroblastoma cells requires endogenous estrogen synthesis and is mediated by mutually repressive MAPK and PI3K cascades. *Mol Cell Endocrinol* 2019;490:68–79